UNSPSC 51283105: Micafungin

This classification denotes an antifungal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R10H71BSWG. European Medicines Agency schedules Micafungin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16444MIG. Micafungin generally arises in the molecular formula C56H71N9O23S. The term MICAFUNGIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 3-4, 2001, list 46.) Most nations schedule micafungin under HS 29419000 and SITC 54139.

UNSPSC 51283105 Micafungin is a Commodity code that nominally describes a single antifungal pharmaceutical product, but recent state and local solicitations tagged under this code show little activity aligned with micafungin procurement itself. Instead, the opportunities reflect broader pharmaceutical and medical supply purchasing by health agencies and local governments — including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, direct-to-manufacturer prescription programs, and medical and first aid supplies for emergency response. The issuing bodies span state health departments (Texas HHS Commission, Minnesota Department of Administration), county health agencies (Seminole County, Florida), municipalities (City of Tampa), and multistate cooperative purchasing alliances (MMCAP). The scope of work under the code's recent opportunities covers emergency medical supplies, naloxone procurement for community health initiatives, pharmacy benefit program sourcing, and first aid and respiratory equipment for fire department rescue operations.

Activity appears concentrated in the South and Upper Midwest, with recent opportunities from Florida, Texas, Minnesota, and Oregon through cooperative purchasing participation. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023), the City of Tampa's IFB for medical and first aid supplies estimated at $700,000 with an SLBE set-aside and 5 percent discount (due March 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026), and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (due April 3, 2026). The code shows sparse, fragmented activity with no pattern suggesting micafungin-specific procurement — the mismatch between the code's nominal scope and the opportunities listed indicates limited relevance for vendors focused on that antifungal product line.